ADAM33 rs7977109: Airway Reactivity and Allergy Risk
The rs7977109 single-nucleotide polymorphism is an intronic variant located within the ADAM33 gene on chromosome 20. Identified in candidate gene and respiratory genetics research, it is moderately associated with allergic hyperresponsiveness, airway remodeling, and susceptibility to chronic respiratory conditions such as asthma. Understanding your genotype provides educational insight into your baseline airway biology rather than a direct diagnosis of respiratory disease.
What each genotype means
Typical ADAM33 profile
This genotype represents the most common genetic configuration for this location in the ADAM33 gene. Research into this variant suggests it is part of a gene associated with airway remodeling and susceptibility to allergic asthma, though individual risk is influenced by many other genetic and environmental factors.
This is the most frequent genotype observed in most global populations.
Increased susceptibility marker
Carrying one copy of the minor allele at this position has been studied in the context of allergic hyperresponsiveness and airway remodeling. While this variant is linked to asthma susceptibility in various studies, it is not a diagnostic marker and does not guarantee the development of any condition.
This heterozygous genotype is found in a significant portion of European and admixed American populations, typically appearing in roughly 1 in 4 to 1 in 5 individuals.
Elevated susceptibility marker
This genotype represents the homozygous state for the minor allele, which has been investigated for its association with bronchial hyperresponsiveness. Because asthma is a complex condition involving gene-environment interactions, this result should be viewed as one small piece of a much larger biological picture.
This genotype is less common than the heterozygous form, occurring in a smaller subset of the population depending on ancestral background.
Genetic Anatomy: What and Where Is rs7977109?
The single-nucleotide polymorphism rs7977109 is located on chromosome 20p13 inside the ADAM33 gene (ADAM metallopeptidase domain 33). Rather than altering the amino acid sequence of a protein directly, rs7977109 resides within an intronic, non-coding region of the gene. Intronic variations often act by modifying gene expression, shifting pre-mRNA alternative splicing patterns, or sitting in tight linkage disequilibrium with neighboring functional variants. Historically, ADAM33 was identified through positional cloning as one of the first major novel susceptibility genes associated with bronchial hyperresponsiveness. Polymorphisms throughout the gene have since been mapped in extensive respiratory cohorts worldwide to elucidate how variations in pulmonary tissue architecture influence susceptibility to allergic and inflammatory insults.
Biological Role: How ADAM33 Influences the Lungs
The ADAM33 gene encodes a membrane-anchored zinc metalloproteinase characterized by disintegrin and peptidase domains. Unlike classic immune-mediated allergy genes such as interleukins or IgE receptors, ADAM33 is selectively expressed in mesenchymal lineages of the lung, notably airway smooth muscle cells, fibroblasts, and myofibroblasts. Enzymatically active soluble fragments of the protein can stimulate angiogenesis and accelerate cell proliferation. Through these pathways, ADAM33 plays a direct role in airway remodeling—a process involving thickening of the bronchial walls, smooth muscle hyperplasia, and altered extracellular matrix turnover. When structural airway cells exhibit dysregulated ADAM33 activity, the respiratory tract can become twitchy or hyperresponsive, lowering the biological threshold required for common allergens to provoke airway constriction and inflammation.
Research Evidence: Allergic Hyperresponsiveness and Asthma
Multiple candidate gene investigations and genetic epidemiology studies have linked polymorphic alleles within ADAM33 to increased susceptibility to asthma, accelerated decline in lung function, and bronchial hyperreactivity. Research published across diverse cohorts reveals moderate statistical associations between specific risk alleles and atopic airway remodeling. However, the evidence remains complex and occasionally heterogeneous across global studies. While some population analyses demonstrate elevated odds ratios for allergic asthma and airway sensitivity, other cohorts have yielded neutral or inconclusive results for individual markers. Because asthma is a multifactorial condition driven by intricate networks of gene-environment interactions, no single ADAM33 variant acts in isolation; rather, rs7977109 serves as one small contributing component in a broader polygenic and environmental landscape.
Interpreting Your Results: Actionable Steps and Limits
Carrying a risk-associated genotype at rs7977109 does not mean you have or will develop asthma, allergies, or chronic obstructive airway disease. Genetics represents an underlying baseline susceptibility, whereas lifestyle, childhood viral exposures, tobacco smoke, air quality, and allergen loads strongly dictate whether respiratory symptoms manifest. This genetic information cannot diagnose respiratory illness or assess clinical lung function. If you experience shortness of breath, chronic wheezing, or frequent allergic flare-ups, consult a physician or pulmonologist for diagnostic pulmonary function testing. Furthermore, never start, alter, or discontinue asthma medications or allergy therapies based on raw genetic data; any therapeutic changes should be supervised by a licensed healthcare professional.
How common is this variant?
The minor susceptibility allele for rs7977109 has an estimated minor allele frequency of approximately 0.15 to 0.25 among European and admixed American populations, with variable frequencies reported across Asian and African ancestral cohorts.
Frequently asked questions
Does carrying the rs7977109 risk allele mean I will get asthma?
No. The variant confers only a modest statistical susceptibility in population studies and is not a deterministic or diagnostic gene test. Many individuals carrying one or two risk alleles never develop asthma or chronic allergies.
How does ADAM33 differ from typical allergy genes?
Unlike traditional allergy genes that govern immune system signaling, such as IgE antibodies or cytokines, ADAM33 functions primarily within the structural cells of the lung, including fibroblasts and airway smooth muscle. It influences how the physical tissues of the airway remodel, heal, and contract in response to environmental triggers.
Can rs7977109 help choose asthma medications?
Current pharmacogenomic guidelines do not recommend adjusting inhaled corticosteroids, bronchodilators, or other therapies based on rs7977109 alone. Medication plans and dosage decisions should always be evaluated by a healthcare professional based on validated clinical guidelines.
What practical steps can I take if I carry an attention-associated genotype?
Focus on actionable environmental lifestyle choices, such as avoiding cigarette smoke, reducing home dust and mold exposures, and optimizing indoor air quality. If you experience recurring coughing, wheezing, or allergic symptoms, discuss them with a clinician for formal evaluation.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7977109?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ADAM33
This variant is part of a haplotype associated with increased risk of asthma in patient populations.
This variant is part of a haplotype associated with increased risk of asthma in patient populations.
Noncoding functional polymorphism in the asthma and allergy risk gene ADAM33 linked to altered bronchial reactivity and atopic susceptibility.
This variant is part of a haplotype in the ADAM33 gene that shows significant association with asthma susceptibility and IgE levels in specific patient populations.